708 event(s) found
APHON-Sponsored Virtual Chemotherapy and Biotherapy Provider Course
The Pediatric Chemotherapy and Biotherapy Provider Course is a 2-day course is designed for license nurses who are new to pediatric and adolescent chemotherapy and biotherapy administration, as well as for those who want a comprehensive review. The Pediatric Chemotherapy Biotherapy Curriculum 4th Edition is the required textbook for all Chemotherapy/Biotherapy Provider Courses.
SITC 2025 (40th Anniversary)
Advancing the Science and Application of Cancer Immunotherapy Worldwide Make your mark at the largest cancer immunotherapy conference and exhibit at SITC’s 40th Anniversary Annual Meeting, hosted by the leading member-driven organization focused on cancer immunotherapy, SITC. At SITC’s Annual Meeting, we will bring together international leaders from academia, regulatory and government agencies, as well as industry representatives for unmatched education, scientific exchange and networking with the scientists driving the field.
SITC Town Hall Webinar: The State of Play in Immunotherapy Research
The Society for Immunotherapy of Cancer (SITC) is pleased to offer the first FREE MEMBER-ONLY webinar in the SITC Town Hall live webinar series, "SITC Town Hall: The State of Play in Immunotherapy Research". Webinar Description: For 40 years, SITC has been the leader in promoting tumor immunology and advancing cancer immunotherapy research and education. Considering that recent federal actions have posed challenges to the biomedical research landscape, we believe it is essential to unite our community to exchange knowledge and share experiences. In addition to facilitating these discussions, SITC is implementing several precautionary measures to safeguard privacy, including prohibiting the recording or distribution of webinars, Q&A anonymity, and enforcing a more secure registration process. Key leaders in the field who are experts in their respective fields will provide an overview of the current state of the science and address questions about its future.
Congrès SFI Paris 2025
La Société Française d’Immunologie (SFI) vous donne rendez-vous du 12 au 14 novembre 2025 à la Cité des Sciences et de l’Industrie (Porte de la Villette, Paris) pour son congrès annuel. Cet événement réunira la communauté des immunologistes autour des dernières avancées en immunologie fondamentale, appliquée et médicale.
ITCC Annual Meeting 2025
The annual meeting of the Innovative Therapies for Children and Adolescents with Cancer (ITCC) consortium
Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology
The Society for Immunotherapy of Cancer (SITC) is pleased to offer the ninth FREE webinar in the SITC-NCI Computational Immuno-oncology live webinar series, "Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology". Webinar Description: In this webinar we will review some methods for extracting information on the tumor immune microenvironment from spatial imaging and spatial genomics assays. We will also explore methods that relate the information obtained from different spatial assay types. Key leaders in the field who are experts in their respective fields will provide an overview of the current state of the science and address questions about its future. Faculty Speaker: Vesteinn Þórsson, PhD – Institute for Systems Biology Moderator: Sandhya Prabhakaran, PhD – Moffitt Cancer Center An interactive Q&A session will follow the topic overview, providing participants with the opportunity to ask in-depth questions of the faculty.
LEUKEMIA 360
The premier international meeting devoted to academia-industry leukemia R&D&I partnering. An event organized by OPALE, The Organization for Partnerships in Leukemia, supported by France's National Cancer Institute and the ARC Foundation for Cancer Research.
LEUKEMIA 360 - 2nd Edition
The premier international meeting devoted to academia-industry leukemia R&D&I partnering. An event organized by OPALE, The Organization for Partnerships in Leukemia, supported by France's National Cancer Institute and the ARC Foundation for Cancer Research.
ITCC Annual Meeting 2025
The annual meeting of the Innovative Therapies for Children and Adolescents with Cancer (ITCC) consortium
ESID EHA SIOPE Focused Symposium 2025: The Interplay of Immunology & Haematology
Join clinical experts, researchers and colleagues to elevate the care and outcomes of our immunodeficiency, haematology and cancer patients. When should we screen our primary immunodeficiency, haematology or oncology patients for underlying or additional risks? How best should we treat oncology/haematology patients with an underlying primary ID or secondary ID? How can we better coordinate with colleagues in other fields to improve care? Whether you are already researching the interplay, are interested in getting involved, or want to advance your clinical practice, the ESID EHA SIOPE Focused Symposium will uniquely offer you expansive opportunities with international leaders. We encourage all to get involved – especially fellows, researchers & junior faculty.
Challenges and Opportunities for Clinical Research in Low and Middle-Income Countries. The SIOP PARC Program
Please join us for the second webinar “Challenges and opportunities for clinical research in low and middle-income countries. The SIOP PARC Program” of our joint 2025 webinar series, where members of SIOP North America Global Health Committee and ASPHO’s Global Special Interest Group (SIG) seek engaging topics and jointly develop the webinar content. The webinar is free of charge and open to all (you will not need to be a SIOP or ASPHO member to join).
ESID EHA SIOPE Focused Symposium 2025: The Interplay of Immunology & Haematology
Join clinical experts, researchers and colleagues to elevate the care and outcomes of our immunodeficiency, haematology and cancer patients. When should we screen our primary immunodeficiency, haematology or oncology patients for underlying or additional risks? How best should we treat oncology/haematology patients with an underlying primary ID or secondary ID? How can we better coordinate with colleagues in other fields to improve care? Whether you are already researching the interplay, are interested in getting involved, or want to advance your clinical practice, the ESID EHA SIOPE Focused Symposium will uniquely offer you expansive opportunities with international leaders. We encourage all to get involved – especially fellows, researchers & junior faculty.
7ème journée "Rencontre Phases Précoces en Cancérologie"
In French: "La Rencontre 2025 Phases Précoces en Cancérologie sera une édition en présentiel au Palais des Congrès d’Issy-Les-Moulineaux pour favoriser les échanges et les débats pour l’ensemble des acteurs présents et impliqués dans ce domaine, avec une ambition commune à tous : « Comment faire de la France le pays le plus attractif pour les phases précoces en cancérologie ? ». Un programme riche, avec des thématiques en ligne avec l’actualité, pour débattre tous ensemble des sujets qui comptent autour des phases précoces en cancérologie."
2025 Hot Topic in Basic & Translational Science: Unraveling Precancer & Early-Stage Lung Cancer
HT25 is your chance to engage with a diverse, international community of scientists, clinicians, diagnosticians, industry leaders, and data experts. This is a rare opportunity to form collaborations that bridge basic research, translational science, and clinical innovation in early lung cancer.
7ème journée "Rencontre Phases Précoces en Cancérologie"
In French: "La Rencontre 2025 Phases Précoces en Cancérologie sera une édition en présentiel au Palais des Congrès d’Issy-Les-Moulineaux pour favoriser les échanges et les débats pour l’ensemble des acteurs présents et impliqués dans ce domaine, avec une ambition commune à tous : « Comment faire de la France le pays le plus attractif pour les phases précoces en cancérologie ? ». Un programme riche, avec des thématiques en ligne avec l’actualité, pour débattre tous ensemble des sujets qui comptent autour des phases précoces en cancérologie."
2025 Hot Topic in Basic & Translational Science: Unraveling Precancer & Early-Stage Lung Cancer
HT25 is your chance to engage with a diverse, international community of scientists, clinicians, diagnosticians, industry leaders, and data experts. This is a rare opportunity to form collaborations that bridge basic research, translational science, and clinical innovation in early lung cancer.
PSCC Lunch & Learn: Speed up blood cancer research with high value added biological resources.
Lunch & Learn: A new format introduced by PSCC Concise, interactive, and hosted onsite at PSCC, this lunch session is designed to foster direct exchanges with an academic expert. The goal: to enable members of the ecosystem to gain first-hand insights on a scientific or strategic topic related to innovation in oncology, in a small-group setting. Featuring Emilie Robert (CRYOSYSTEM).
Convention nationale des Centres de lutte contre le cancer
In French: "La Convention nationale des Centres de lutte contre le cancer revient en 2025 avec un riche programme mettant à l’honneur les défis de la cancérologie de demain et les dynamiques territoriales qui la portent."
PSCC Lunch & Learn: Speed up blood cancer research with high value added biological resources.
Lunch & Learn: A new format introduced by PSCC Concise, interactive, and hosted onsite at PSCC, this lunch session is designed to foster direct exchanges with an academic expert. The goal: to enable members of the ecosystem to gain first-hand insights on a scientific or strategic topic related to innovation in oncology, in a small-group setting. Featuring Emilie Robert (CRYOSYSTEM).
Plateforme de modélisation ex-vivo des cancers et criblages fonctionnels (OrganoScreen)
In French: "Ne manquez pas le prochain petit-déjeuner Ecosystem sur le thème : Plateforme de modélisation ex-vivo des cancers et criblages fonctionnels (OrganoScreen). Avec : Pierre Savagner est chercheur en biologie du développement au CNRS et co-directeur de la plateforme de modélisation ex-vivo des cancers et criblages fonctionnels depuis l’été 2025. Julie Rivière est ingénieure de Recherche en Biologie INSERM à Gustave Roussy, elle est co-directrice de la plateforme de modélisation ex-vivo des cancers et criblages fonctionnels depuis février 2025."
AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology
The Society for Immunotherapy of Cancer (SITC) is pleased to offer the tenth and final FREE webinar in the SITC-NCI Computational Immuno-oncology live webinar series, "AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology". Webinar Description: Patient burden dynamics, serum, tumor genomic, and functional profiles contain valuable insights for cancer research. This webinar demonstrates how AI, computational, and mathematical driven approaches can integrate these profiles to model the tumor-microenvironment interactions, discover novel IO targets and biotherapeutics, predict patient responses to immunotherapy, elucidate mechanisms of IO resistance, and develop therapies that exploit drug dosing and sequencing. Key leaders in the field who are experts in their respective fields will provide an overview of the current state of the science and address questions about its future. AI Leader Faculty: Xiaole Shirley Liu, PhD – GV20 Therapeutics Clinician Faculty: Marco L. Davila, MD, PhD – Roswell Park Comprehensive Cancer Center Mathematician Faculty: Alexander Anderson, PhD – Moffitt Cancer Center Moderator: Carsten Krieg, PhD – Medical University of South Carolina An interactive Q&A session will follow the topic overview, providing participants with the opportunity to ask in-depth questions of the faculty.
Plateforme de modélisation ex-vivo des cancers et criblages fonctionnels (OrganoScreen)
In French: "Ne manquez pas le prochain petit-déjeuner Ecosystem sur le thème : Plateforme de modélisation ex-vivo des cancers et criblages fonctionnels (OrganoScreen). Avec : Pierre Savagner est chercheur en biologie du développement au CNRS et co-directeur de la plateforme de modélisation ex-vivo des cancers et criblages fonctionnels depuis l’été 2025. Julie Rivière est ingénieure de Recherche en Biologie INSERM à Gustave Roussy, elle est co-directrice de la plateforme de modélisation ex-vivo des cancers et criblages fonctionnels depuis février 2025."
ICHO-25: International Conference on Hematology and Oncology
Science Cite is delighted to welcome you to the International Conference on Hematology and Oncology at Tianjin,China on 04th - 05th Dec 2025. It's our pleasure to have a platform with all the field's leading scientists, outstanding researchers, academic people, and industrialists from national and international locations. All attendees and the domain will benefit from the discussions at conferences, seminars, workshops, symposia, and other related events. In addition, we offer a platform for all academicians to display their research and ideas and explore speaking opportunities. In addition to being united by a common goal - to provide information exchange and advance the fields. This conference will help you all make new connections, gain recognition and receive feedback to help you grow personally and professionally. Our goal is to create a motivating atmosphere and to discuss solutions, future strategies, and trends. Therefore, we look forward to your participation which means gaining immense exposure and helping people.
North American Conference on Lung Cancer (NACLC)
We are excited to bring together experts, researchers, and clinicians for a dynamic in-person experience. NACLC has a strong tradition of fostering collaboration and, in 2025, we continue this legacy with cutting-edge research, diverse educational sessions, and unparalleled networking opportunities. Join us as we explore the latest advancements in prevention, detection, and care for thoracic malignancies, with insights from thought-leaders in the field. Whether you are attending for the first time or are a returning participant, we look forward to engaging discussions and shared learning that will shape the future of lung cancer care.